Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability
Yuichi Horigome, Koichi Ehata, Noriyuki Tadera, Kei Hayama, Hirotoshi Kamata, Takahiro Suzuki et al. Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability. // Blood Research. – 2026. – DOI: 10.1007/s44313-026-00165-y. – URL: https://doi.org/10.1007/s44313-026-00165-y
Yuichi Horigome, Koichi Ehata, Noriyuki Tadera, Kei Hayama, Hirotoshi Kamata, Takahiro Suzuki, & Koji Miyazaki (2026). Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability. Blood Research. https://doi.org/10.1007/s44313-026-00165-y
Yuichi Horigome, et al. “Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability.” Blood Research, 2026. doi:10.1007/s44313-026-00165-y.
@article{Horigome2026,
title = {Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability},
author = {Horigome, Yuichi and Ehata, Koichi and Tadera, Noriyuki and Hayama, Kei and Kamata, Hirotoshi and Suzuki, Takahiro and Miyazaki, Koji},
journal = {Blood Research},
year = {2026},
doi = {10.1007/s44313-026-00165-y},
url = {https://doi.org/10.1007/s44313-026-00165-y}
}